Answers are grounded in this paper and cite their sources.
Pulmonary arterial hypertension is a disease characterized by progressive resistance to flow across the pulmonary vascular bed, resulting in death from progressive right heart failure. The evolution of the currently approved therapies for certain pulmonary arterial hypertension functional classes has resulted in a considerable improvement in 1-year survival. However, substantial risk remains. For those patients judged to be deteriorating on therapy, bilateral sequential lung transplant or, occasionally, heart-lung transplant is the preferred option. Review of the literature suggests many relatively simple, routinely acquired clinical and hemodynamic indices that appear to predict risk of mortality and hence need for transplant. The current LAS, in sharp contrast, substantially disenfranchises patients with pulmonary arterial hypertension. It is hoped that validation of some or all of these risk factors, as is being undertaken in the REVEAL database, may permit development of a reliable, simple, and widely applicable tool for assessing mortality risk and hence need for transplant referral in our PAH patients.
No takes yet. Share an insight, caveat, or question.
Adaani Frost (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: